The aim of this study was; evaluating MIC values of P. aeruginosa isolates which were isolated from clinical specimens according to the CLSI 2011. [4] CLSI 2012 [3] and European Committee on Antimicrobial Susceptibility Testing (EUCAST) [5] guidelines, to reveal differences in susceptibility rates and to contribute to the debate on guide exchange.
A total of 3632 strains for imipenem, 3706 strains for meropenem, 3479 strains for piperacillin and 4760 strains for piperacillin-tazobactam were enrolled in this study. Identification of the strains and MIC values have been studied in Phoenix (BD Diagnostic, ABD) and Vitek2 (Biomerieux, France) automated systems.
When compared CLSI 2011 and 2012 criteria, it was observed that the rate of imipenem-susceptible strains were decreased from 58% to 54 5% and the rate of intermediate strains were increased from 4% to 7 5%. Furthermore, similar changes have been seen for meropenem and 4% decrease was observed for susceptible strains. However, 10% decrease was determined for the rate of susceptible strains for piperacillin and piperacillin-tazobactam [ Table 1 ]. According to EUCAST criteria, while MIC values for imipenem is similar to CLSI 2011, susceptible strain rate same with CLSI 2011 and it was determined to be higher according to CLSI 2012. MIC values in EUCAST for piperacillin and piperacillin-tazobactam is lower and the susceptibility MIC value is same with CLSI 2012. 
